Please login to the form below

Not currently logged in
Email:
Password:

The Sudler London Award for Excellence in Mature Brand Revitalisation

Sponsored by

Finalist

AmBisome – Winning the Battle for Hearts and Minds

Gilead in association with Langland


Summary of work

Effective clinical decision-making is vital when managing invasive fungal infections. The immuno-compromised, including cancer and intensive care patients, can succumb to infection and rapidly deteriorate. Delaying or choosing an inappropriate treatment option can be fatal. 

Launched in 1990, Gilead’s AmBisome (liposomal amphotericin B) became the gold standard within the anti-fungal category. However during the following 20 years, the landscape changed. Competitor brands aligned themselves to the two major pathogen classes, effectively bisecting the market and niching AmBisome.

With AmBisome’s market share declining year-on-year, the brief to the 2010 global brand team was simple – keep it ticking over. 

Instead, with cross-functional team-work and customer engagement, AmBisome was cleverly repositioned. Despite being in a functional-led category, the brand was aligned to a key emotional driver, realised through powerful creative work. Enabling the brand to challenge customers’ mindsets. Coupled with a strong clinical rationale, the campaign targeted diversified key segments and delivered consistently through innovative tactics. 

Effective affiliate management led to excellent local implementation. Following years of declining performance, AmBisome, two decades post-launch, demonstrated market share growth. Internal attitudes were transformed and the campaign became a catalyst for a new chapter in its life cycle. 

 

 

Executive summary as submitted


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics